eCommons@AKU
Department of Medicine

Department of Medicine

December 2011

Interferon alpha for chronic Hepatitis D
Zaigham Abbas
Agha Khan University, zaigham.abbas@aku.edu

Muhammad Arsalan Khan
Mohammad Salih
Aga Khan University

Wasim Jafri
Aga Khan University, wasim.jafri@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Gastroenterology Commons, Oncology Commons, and the Virus Diseases Commons
Recommended Citation
Abbas, Z., Khan, M., Salih, M., Jafri, W. (2011). Interferon alpha for chronic Hepatitis D. Cochrane Database of Systematic Reviews(12),
6002-6002.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med/61

Cochrane Database of Systematic Reviews

Interferon alpha for chronic hepatitis D (Review)
Abbas Z, Khan MA, Salih M, Jafri W

Abbas Z, Khan MA, Salih M, Jafri W.
Interferon alpha for chronic hepatitis D.
Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD006002.
DOI: 10.1002/14651858.CD006002.pub2.

www.cochranelibrary.com

Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

TABLE OF CONTENTS
HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACKNOWLEDGEMENTS
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Mortality, Outcome 1 Interferon alpha versus no intervention. . . . . . . . . .
Analysis 2.1. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 1 Failure of virological
response: end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 2.2. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 2 Failure of virological
response: six months after completion of treatment. . . . . . . . . . . . . . . . . . . . . .
Analysis 2.3. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 3 Failure of biochemical
response: end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 2.4. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 4 Failure of biochemical
response: six months after completion of treatment. . . . . . . . . . . . . . . . . . . . . .
Analysis 2.5. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 5 Failure of histological
response. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 3.1. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 1 Failure of virological response:
end of treatment.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 3.2. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 2 Failure of virological response:
six months after completion of treatment. . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 3.3. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 3 Failure of biochemical
response: end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 3.4. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 4 Failure of biochemical
response: Six months after completion of treatment.
. . . . . . . . . . . . . . . . . . . .
ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
INDEX TERMS
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
1
2
3
3
3
6
7
9
10
12
13
13
14
18
28
29
30
31
32
33
34
35
35
36
37
37
39
40
41
41
41
41

i

[Intervention Review]

Interferon alpha for chronic hepatitis D
Zaigham Abbas1 , Muhammad Arsalan Khan2 , Mohammad Salih3 , Wasim Jafri3
1
Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. 2 Department of Hepatobiliary Surgery, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. 3 Department of Medicine, Aga Khan University
Hospital, Karachi, Pakistan

Contact address: Zaigham Abbas, Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Diwan
Complex, Chand Bibi Road, Karachi, Sindh, Pakistan. drzabbas@gmail.com.
Editorial group: Cochrane Hepato-Biliary Group.
Publication status and date: New, published in Issue 12, 2011.
Citation: Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database of Systematic Reviews
2011, Issue 12. Art. No.: CD006002. DOI: 10.1002/14651858.CD006002.pub2.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT
Background
Hepatitis D virus is a small defective RNA virus that requires the presence of hepatitis B virus infection to infect a person. Hepatitis D
is a difficult-to-treat infection. Several clinical trials have been published on the efficacy of interferon alpha for hepatitis D virus (HDV)
infection. However, there are few randomised trials evaluating the effects of interferon alpha, and it is difficult to judge any benefit of
this intervention from the individual trials.
Objectives
To evaluate the beneficial and harmful effects of interferon alpha for patients with chronic hepatitis D.
Search methods
We identified relevant for the review randomised clinical trials by electronic searches in the Cochrane Hepato-Biliary Group Controlled
Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE,
and Science Citation Index Expanded until May 2011. We also checked the bibliographic references of identified randomised trials,
textbooks, and review articles in order to find randomised trials not identified by the electronic searches.
Selection criteria
Randomised clinical trials evaluating interferon alpha versus placebo or no intervention for patients with chronic hepatitis D infection.
Data collection and analysis
Two authors assessed the trials and extracted data on mortality, virologic, biochemical, and histological response as well as adverse
events at end of treatment and six months or more after completing treatment. The analyses were performed using the intentionto-treat principle including all randomised participants irrespective of follow-up. Drop-outs, withdrawals, and non-compliance were
considered as treatment failures. Data were analysed with fixed- and random-effects models. Reported results were based on fixed-effect
model except in cases where statistical significance varied between the two models.
Interferon alpha for chronic hepatitis D (Review)
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Main results
Six randomised trials fulfilled the inclusion criteria. Two hundred and one randomised participants (male = 174) were included. The
risk of bias in all the included trials was high. Five trials compared interferon alpha with no treatment in the control group. One of these
trials had two treatment arms with a higher dose and lower dose of interferon alpha and a no-treatment control group. We analysed
both treatment regimens as a single group in a primary analysis and as separate groups in the subgroup analysis of different interferon
dosages. The sixth trial compared only a higher dose of interferon alpha with a lower dose.
Meta-analysis of five trials comparing interferon alpha with no-treatment control group included 169 participants. There were seven
drop-outs in the treatment group and nine in the control group. One patient out of 92 (1.1%) died in the interferon alpha group
compared with zero out of 77 (0.0%) in the no-intervention control group (risk ratio (RR)) 3.00; 95% confidence interval (CI) 0.14
to 66.5). Interferon alpha led to failure of end of treatment virological response in 62/92 (67.4%) of the patients compared with 71/
77 (92.2%) in the untreated controls (RR 0.76, 95% CI 0.66 to 0.87, P = 0.0001 by fixed-effect model and RR 0.71, 95% CI 0.43 to
1.16, P = 0.17 by random-effects model). Failure of normalisation of alanine aminotransferase (ALT) at the end of treatment was seen
in 60/92 (65.2%) patients treated with interferon alpha versus 76/77 (98.7%) in the control group (RR 0.69, 95% CI 0.59 to 0.80, P
< 0.00001). Sustained virological response was not achieved in 76/92 (82.6%) of patients on interferon compared with 73/77 (94.8%)
of controls (RR 0.89, 95% CI 0.80 to 0.98, P = 0.02). Serum alanine aminotransferase was abnormal in 81/92 (88.0%) treated with
interferon alpha patients at six months post-treatment follow-up compared with 76/77 (98.7%) in controls (RR 0.92, 95% CI 0.84 to
0.99, P = 0.04). There was no significant histological improvement in 67/92 (72.8%) patients treated with interferon alpha compared
with 65/77 (84.4%) in controls (RR 0.86, 95% CI 0.74 to 1.00, P = 0.06).
Two trials comparing a higher dose of interferon alpha with the lower dose showed no significant difference in sustained virological
response (76.7% compared with 90.0%) (RR 0.85, 95% CI 0.68 to 1.07, P = 0.16). Adverse events such as flu-like symptoms, asthenia,
weight loss, alopecia, thrombocytopenia, and leukopenia were reported in all these trials and the adverse events were related to interferon
alpha. These were common and sometimes severe. One patient in the treatment group was reported to have died by suicide towards
the end of the study period.
Authors’ conclusions
Interferon alpha does not seem to cure hepatitis D in most patients. The agent seems effective in suppressing viral and liver disease
activity in some patients, but this improvement is not sustained in the majority of patients. We cannot exclude overestimation of benefits
and underestimation of harms due to high risk of bias (systematic errors) and high risk play of chance (random errors). Therefore, more
randomised trials with large sample sizes and less risk of bias are needed before interferon can be recommended or refuted.

PLAIN LANGUAGE SUMMARY
Interferon alpha for patients with chronic hepatitis D
Hepatitis D virus is unique in that it can only infect a person who is already infected by hepatitis B virus. Chronic hepatitis D is a
difficult-to-treat infection. Several antiviral and immunomodulating agents have been evaluated in treatment of hepatitis D. However,
with the exception of interferon, all of them proved ineffective. This meta analysis of six randomised clinical trials of interferon shows
that even Interferon alpha is not an ideal drug for this infection. Among the 169 participants included in primary meta analysis,
interferon alpha induced loss of virus, normalisation of liver tests, and improvement in the liver biopsy in more patients compared
with those who were left untreated. Unfortunately, most of these patients did not have sustained response after stopping treatment.
Additional analysis of two trials comparing a higher dose of interferon alpha with lower dose among randomly assigned participants
showed no significant difference in outcome between the two groups. There were differences in dosage and duration of interferon alpha
used among included trials as well as some other methodological weakness which places a high risk of bias in this meta analysis.
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BACKGROUND
Hepatitis D virus (or delta virus) (HDV) is a defective small single-stranded circular RNA virus that requires the helper function
of hepatitis B virus (HBV) for viral assembly and propagation
(Rizzetto 1977). Acute infection with HDV acquired by coinfection with HBV is often severe. However, most patients achieve
usually a complete recovery and only 2% of the patients progress
to chronicity (Farci 2003). Superinfection of HDV in persons
with HBV infection leads to progressive disease and cirrhosis in
approximately 80% of patients (Rizzetto 2003). Cirrhosis develops earlier in HDV-infected patients than patients infected only
with chronic HBV (Rizzetto 1983; Hughes 2011). Up to 5% of
the world’s population is infected with HBV, and probably 5%
of the HBV carriers have HDV superinfection (Gaeta 2001). Accordingly, about 15 million people may have chronic hepatitis D
infection.
HDV is difficult to eradicate as most of the possible therapeutic
targets are normal cellular proteins. The sole enzymatic activity
that HDV possesses is a ribozyme that autocleaves the circular
RNA, producing a linear molecule (Sharmeen 1988). Concomitant infection with an RNA (HDV) and a DNA (HBV) virus
makes chronic hepatitis D more difficult to treat than chronic hepatitis B alone. As with hepatitis B, poor results were obtained in the
treatment of hepatitis D with immunosuppressive and immunostimulant drugs (Arrigoni 1983; Rizzetto 1983). The mechanism
of action of interferon in chronic hepatitis D is poorly understood.
In HDV transfected hepatoma cell lines, HDV replication was not
affected by interferon (Ottobrelli 1991; Ilan 1992). In vitro experiments apparently contrast with the results observed in patients, in
whom response to interferon is often characterised by a concomitant reduction in HDV viraemia and in alanine aminotransferase
(ALT) levels, suggesting a direct antiviral effect of interferon on
HDV.
Several clinical trials on the long-term administration of interferon were undertaken in the late 1980s (Farci 1994; Malaguarnera
1996). The response, assessed by the normalisation of serum alanine aminotransferase (ALT) levels and clearance of serum HDV
RNA varied widely. Moreover, it occurred at different times from
the beginning of treatment, sometimes even after discontinuation
of interferon. The proportion of patients with response and relapse
seemed proportional to the dose of interferon (Di Bisceglie 1990;
Madejon 1994). Sustained responses were unusual and often incomplete, showing persistently normal ALT despite the recrudescence of HDV viraemia. Concomitant sustained biochemical and
virological responses were usually accompanied by the clearance
of serum hepatis B surface antigen (HBsAg) and seroconversion
to anti-HBs antibody (Battegay 1994).
Farci et al demonstrated that interferon alpha, given in a dose of 9
million units three times a week for 48 weeks, was generally well
tolerated and resulted in clearance of serum HDV RNA, normal

ALT values, and histologic improvement in 50% of patients with
chronic hepatitis D (Farci 1994). A complete biochemical response
persisted for up to four years in half the patients who had normal
ALT values at the end of therapy, whereas the effects on viral
replication were not sustained in these patients. Niro et al reviewed
the trials on the treatment of hepatitis D and concluded that the
medical treatment of chronic hepatitis D rested on interferon,
which should be administered at high doses (9 to 10 million units
three times a week) to patients with compensated liver disease
and as soon as chronic HDV disease was diagnosed (Niro 2005).
Treatment should be prolonged for 12 months as response, ie,
clearance of HDV RNA and normalisation of ALT levels, can be
delayed and sometimes occur after the end of the treatment.
There is one previous meta-analysis available dealing with interferon alpha for hepatitis D (Hadziyannis 1991). It is based on reduction in ALT levels as the primary outcome measure. We could
not find any comprehensive meta-analyses that evaluated interferon alpha for chronic hepatitis D in terms of mortality and virological, biochemical, and histological responses at the end of treatment and the end of the follow-up. Therefore, we felt the need to
perform the present Cochrane systematic review.

OBJECTIVES
To evaluate the beneficial and harmful effects of interferon alpha
in the treatment of patients with chronic hepatitis D infection.

METHODS

Criteria for considering studies for this review

Types of studies
Randomised clinical trials irrespective of language, publication
date, or blinding.
Types of participants

Inclusion criteria

Included in this analysis were patients with chronic hepatitis D
infection. That is, patients with detectable serum HDV RNA for
at least six months with inactive or active HBV carrier state, and
active inflammatory disease, ie, persistent or intermittent raised activities of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) above the upper limit of normal values (Farci
1994). Patients with compensated delta virus related cirrhosis were
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included as well. Patients with hepatitis C virus and HIV co-infection, alcoholism, patients using immunosuppressive drugs, and
liver transplanted patients were also considered for inclusion in
subgroup analyses.
Exclusion criteria

Patients with acute hepatitis D (ie, acute co-infection with HDV
and HBV or acute HDV superinfection on HVB).

Searching other resources
We also checked the bibliographic references of identified randomised trials, textbooks, and review articles in order to find randomised trials not identified by the electronic searches.

Data collection and analysis
Selection of studies

Types of interventions
Standard interferon alpha or pegylated interferon alpha versus
placebo or no intervention. Interferon alpha could be administered
in any dosage via the subcutaneous or intramuscular route. We
considered for inclusion also trials with co-interventions if these
were administered equally to the relevant intervention groups.
Types of outcome measures
Primary outcomes
1. Mortality.
2. Failure of sustained virologic response: number of patients with
positive HDV RNA at six months or more after treatment.
3. Adverse events: any unfavourable or unintended sign (including
an abnormal laboratory finding), symptom, or disease (new or exacerbated) associated with use of a medicinal product (ICH-GCP
1997). These include serious or minor; expected or unexpected;
and study-related, possibly study-related, or not study-related
events.This also included patients developing decompensation
during interferon therapy.
4. Quality of life.
Secondary outcomes
1. Failure of sustained biochemical response: failure of normalisation of ALT and/or AST levels at six months or more after treatment.
2. Failure of histological response: failure of improvement of inflammatory activity as assessed by liver biopsy.

Search methods for identification of studies

Electronic searches
Relevant randomised clinical trials were identified by electronic
searches in the Cochrane Hepato-Biliary Group Controlled Trials
Register (Gluud 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE,
EMBASE, and Science Citation Index Expanded (Royle 2003).
Last date of search was May 31, 2011. Search strategies applied
to the individual electronic databases with the time span of the
searches are given in Appendix 1.

We retrieved the full paper articles for assessment, and review
authors applied the inclusion criteria to the trials of interest to the
review independently of each other. There were no disagreements
among the authors.
Data extraction and management
Two authors (ZAB and MAK) extracted the following prespecified
characteristics of all included randomised clinical trials independently. In case of discrepancy, the opinion of the third reviewer
(WJA or MSA) was sought in order to reach consensus. Data included:
• Participants: age, sex, ethnic origin, form(s) of transmission,
previous antiviral treatment, presence of cirrhosis at entry,
criteria used to classify chronic hepatitis D, number of patients
randomised, reasons for withdrawal from the trial.
• Interventions: dosage and duration of therapy, and method
of administration, intervention in the control group, and any cointerventions.
• Outcomes: as listed above under outcome measures.
Assessment of risk of bias in included studies
The methodological quality of a trial can affect the estimate of
intervention efficacy (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008; Gluud 2011). Risk of bias of the randomised clinical
trials was assessed using the definitions of following domains (
Higgins 2011).
Sequence generation
- Low risk of bias: sequence generation was achieved using computer random number generation or a random number table.
Drawing lots, tossing a coin, shuffling cards, and throwing dice
are also adequate if performed by an independent adjudicator.
- Uncertain risk of bias: the trial is described as randomised but
the method of sequence generation was not specified.
- High risk of bias: the sequence generation method is not, or
may not be, random. Quasi-randomised studies, those using dates,
names, or admittance numbers in order to allocate patients are
inadequate and were excluded for the assessment of benefits but
not for the assessment of harms.
Allocation concealment
- Low risk of bias: allocation was controlled by a central and independent randomisation unit, serially numbered, opaque and

Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

4

sealed envelopes, or similar, so that intervention allocations could
not have been foreseen in advance of, or during, enrolment.
- Uncertain risk of bias: the trial was described as randomised but
the method used to conceal the allocation was not described, so
that intervention allocations may have been foreseen in advance
of, or during, enrolment.
- High risk of bias: if the allocation sequence was known to the
investigators who assigned participants or if the study was quasirandomised. Quasi-randomised studies were excluded for the assessment of benefits but not for the assessment of harms.
Blinding
- Low risk of bias: the trial was described as blinded, the parties
that were blinded, and the method of blinding was described, so
that knowledge of allocation was adequately prevented during the
trial.
- Uncertain risk of bias: the trial was described as blind, but the
method of blinding was not described, so that knowledge of allocation was possible during the trial.
- High risk of bias: the trial was not blinded, so that the allocation
was known during the trial.
Incomplete outcome data
- Low risk of bias: the numbers and reasons for dropouts and
withdrawals in all intervention groups were described or if it was
specified that there were no dropouts or withdrawals.
- Uncertain risk of bias: the report gave the impression that there
had been no dropouts or withdrawals, but this was not specifically
stated.
- High risk of bias: the number or reasons for dropouts and withdrawals were not described.
Selective outcome reporting
- Low risk of bias: pre-defined, or clinically relevant and reasonably
expected outcomes are reported on.
- Uncertain risk of bias: not all pre-defined, or clinically relevant
and reasonably expected outcomes are reported on or are not reported fully, or it is unclear whether data on these outcomes were
recorded or not.
- High risk of bias: one or more clinically relevant and reasonably
expected outcomes were not reported on; data on these outcomes
were likely to have been recorded.
If a trial obtained the judgement ’low risk of bias’ in all the six
bias risk domains, then it was categorised as a trial with low risk
of bias for the purpose of data analyses. In all other cases, the trial
was categorised as a trial with high risk of bias.

Review Manager software (RevMan) was used for the data analysis
(Deeks 2011; RevMan 2011). Continuous outcomes are expressed
as mean differences (MD) with 95% confidence intervals (CI).
For dichotomous variables we calculated relative risk with 95%
CI. Intention-to-treat principle was applied everywhere.
Heterogeneity between trials was explored by considering the bias
risk of trials, clinical setting, and patients involved. Chi-squared
test for heterogeneity was used to provide an indication of between trials heterogeneity. In addition, the degree of heterogeneity
observed in the results was quantified using the I-squared statistic (Higgins 2003). The heterogeneity statistic I2 , interpreted as
“the percentage of variability due to heterogeneity between studies
rather than sampling error depends on precision, that is, the size
of the studies included” (Rücker 2008).

Assessment of reporting biases
Regression asymmetry test to assess funnel plot asymmetry was
to be employed to indicate the presence of bias (Egger 1997).
However, we did not identify a sufficient number of trials in order
to draw it.

Data synthesis
We analysed the data with both fixed-effect (DeMets 1987) and
random-effects (DerSimonian 1986) model meta-analyses. In case
there was no difference in statistical significance between the results obtained with the two models, we presented the results of
the fixed-effect model analyses. Otherwise, we presented the results of both analyses. The I2 statistic was presented as a measure
of the percentage of variation due to heterogeneity rather than
chance (Higgins 2003). The analyses were performed using the
intention-to-treat principle including all randomised participants
irrespective of follow-up. Drop-outs, withdrawals and non-compliance were considered as treatment failures. Details are given in
’early stopping’ section.
From the data generated by each included randomised clinical
trial, risk ratio was calculated for categorical outcome data and
standardised mean differences for continuous data along with their
95% CI. The results from comparable groups of trials were pooled
into statistical meta-analysis using RevMan (RevMan 2011). Heterogeneity between combined trials was tested using standard chisquare test. Where statistical pooling was not possible, the findings
were summarised by listing and narrating.

Dealing with missing data
An intention-to-treat analysis included all randomised participants. Any missing observations were assumed to have a poor outcome.

Assessment of heterogeneity

Subgroup analysis and investigation of heterogeneity
We performed the following subgroup analyses:
- lower median dose of interferon compared to upper median dose
of interferon (Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis
3.4).
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We could not perform the below listed subgroup analyses either
because there were no sufficient data in the included trials or because the topic was not addressed.
- trials with low risk of bias compared to trials with high risk of
bias;
- trials with short follow-up (less than six months) compared to
trials with long follow-up (more than twelve months);
- pretreatment levels of ALT and/or AST;
- types of interferon administered;
- adult compared to paediatric patients;
- patients with coinfection with hepatitis C virus or HIV compared
to patients without coinfection;
- patients with alcohol problems compared to patients without
coinfection;
- patients with immunosuppressive drugs compared to patients

without coinfection;
- patients with liver transplantation compared to patients without
liver transplantation.

RESULTS

Description of studies
Results of the search
The search strategy identified 35 studies for consideration, out of
which six trials fulfilled the criteria for inclusion and were used for
our meta-analyses (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Six trials with 201 randomised participants provided data for analysis; 174 were males and 27 were women (Table 1). Five trials
compared interferon monotherapy versus no intervention control (Porres 1989; Rosina 1989; Rosina 1991; Farci 1994; Gaudin
1995). A total of 169 patients were included in these five trials;
92 in the intervention group and 77 in the no intervention group.
The baseline characteristics of the patient sample included in the
trials did not show any substantial differences between the groups
in the individual trials as well as across the trials. These trials had
methodological heterogeneity in terms of dosage regimen of interferon alpha and duration of administration of interferon (refer to Characteristics of included studies table). The duration of
treatment was one year in three trials, six months in one (Porres
1989), and three months in another trial (Rosina 1989). Out of
the five trials mentioned above, four trials (Porres 1989; Rosina
1989; Rosina 1991; Gaudin 1995) randomised patients to interferon alpha versus no intervention in the control group. The fifth
trial (Farci 1994) had three groups; two interferon alpha intervention groups and a control group with no treatment. The interferon
groups tested a lower dose (3 million units thrice a week) and a
higher dose (9 million units thrice a week). We analysed both treatment regimens as a single group in a primary analysis (Analysis

2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5) and as
separate groups in the analysis of different interferon dosages. The
remaining trial (Madejon 1994) compared a higher dose of interferon alpha (18 million units thrice a week for 6 months, 9 million
units thrice a week for 1 month, 6 million units tiw for 1 month,
3 million units thrice a week for 4 months) versus a lower dose (3
million units daily for 3 months then 1.5 million units daily for 9
months) of interferon alpha. We have included the Madejon 1994
trial in a subgroup analysis (Analysis 3.1; Analysis 3.2; Analysis
3.3; Analysis 3.4),

Excluded studies
Among the 29 excluded studies, two studies lacked a well-described control group (Borghesio 1995; Di Marco 1996). The remainder were not randomised clinical trials or addressed different
topics (Characteristics of excluded studies).

Risk of bias in included studies
The risk of bias domains were utilised to evaluate the individual
trial for risk of systematic error (Higgins 2011). The results are
summarised in Figure 2 and Figure 3. All the trials had high risk
of bias.
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Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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Figure 3. Methodological quality graph: review authors’ judgments about each methodological quality item
presented as percentages across all included studies.

Allocation
All of the included trials randomly allocated patients to comparison groups. Four trials had computer-generated allocation sequence, and the process was regarded as adequate. In Porres 1989
and Rosina 1989, the authors did not give sufficient details regarding the method used and simply stated that the patients were
randomly allocated into two groups.
Regarding concealment of allocation, Farci 1994 was the only positive exception using computer-generated sealed envelopes. Even
this trial does not mention whether the envelopes were opaque or
not, or if they were consecutively numbered. None of the other
included trials mentioned a specific process of concealment. This
was regarded as lack of concealment.

Blinding
None of the included trials utilised blinding.

Incomplete outcome data
The included trials generally accounted for all the participants.
Outcome variables were identical, and outcomes data were complete in nearly all the trials. The only exception to this was
Porres 1989, where the outcome variables were not clearly defined. Nonetheless, we attempted to assess the results based on
established criteria for end of treatment response and sustained
virological response. These criteria provided a fair representation
of the trials. Wherever missing data were found, assessment was

based on an intention-to-treat principle, and a failure of treatment
was presumed. This happened mostly in case of a second biopsy,
which was not done in all the participants.

Selective reporting
All the included trials were considered free of selective reporting. Every trial reported on the predetermined outcomes for each
patient included, according to the trial report. We acknowledge,
however, that we did not have access to any of the trial protocols.

Other potential sources of bias
Baseline imbalance
The baseline characteristics of patients between experimental and
control groups were similar. The only possible exception was the
apparent disparity in the duration of disease between the two
groups in Madejon 1994 (62.6 ± 10.4 months in low dose interferon versus 49.7 ± 9.8 in high dose group).
Early stopping
In Rosina 1991 interferon was discontinued permanently in five
patients. Reasons were ulcer at the injection site in one patient,
acute icteric hepatitis in another, and non-compliance in three.
Eight untreated patients were withdrawn from the control group
for noncompliance. In Farci 1994, one patient was lost to followup in the control group. Madejon 1994: Drop outs and withdrawals were seven; three from the low dose and four from the
high dose group. Reasons were return to active drug abuse (n =
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2), neuropsychiatric disorder (n = 2), thrombocytopoaenia (n =
2), and voluntary withdrawal (n = 1).Gaudin 1995: Therapy was
discontinued in two patients; one at four months because of induction of hyperthyroidsm and the other at 11 months because
of committed suicide. There were no drop-outs or early stopping
in Porres 1989 and Rosina 1989.
Unit-of-analysis bias
There was a clear methodological heterogeneity among the trials as
already alluded to earlier. In one trial (Farci 1994), multiple treatment groups were employed. The groups were then redefined to
ensure simplified pair-wise comparison for a representative analysis. This may have resulted in a potential unit-of-analysis bias for
the meta-analysis.

Effects of interventions

3). Among the first set of complications, nearly every patient experienced flu-like symptoms across the trials. Other commonly
reported adverse events included anorexia, nausea, weight loss,
alopaecia, leukopaenia, and thrombocytopaenia.

Quality of life
None of the trials reported on the quality of life.

Failure of sustained biochemical response
At six months follow-up, ALT was abnormal in 88.0% treated
patients versus 98.7% controls (RR 0.92, 95% CI 0.84 to 0.99,
P = 0.04) (Analysis 2.4). There was no significant heterogeneity
among the trials on these counts (end of treatment: I2 = 0%, P =
0.57, sustained biochemical response I2 = 0%, P = 0.41).

Interferon alpha versus no intervention

Mortality
One patient in the interferon alpha group was reported to have
died by suicide towards the end of the study period (Gaudin 1995).
No other trials reported any deaths during the treatment or followup period (Analysis 1.1).

Failure of sustained virologic response
A total of 169 patients were included in five trials; 92 in the intervention group and 77 in the no intervention group. There were
seven drop-outs in the treatment group and nine in the control
group. By intention to treat analysis, failure of sustained virological
response (SVR) at six months follow-up was observed in 82.6%
in patients on interferon alpha compared with 94.8% in controls
(RR 0.89, 95% CI 0.80 to 0.98, P = 0.02) (Analysis 2.2). I2 of
41% also indicated a more homogenous distribution among the
meta-analysed groups.
Interferon alpha administration led to failure of end of treatment
response in 67.4% of the patients compared with 92.2% in controls based on clearance of HDV DNA (RR 0.76, 95% CI 0.66
to 0.87, P = 0.0001 by fixed-effect model, RR 0.71, 95% CI 0.43
to 1.16, not significant by random-effects model) (Analysis 2.1).
There was considerable heterogeneity in pooled results (I2 = 89%,
P < 0.00001).

Adverse events
All the trials included in the analysis reported on adverse events
related to administration of interferon alpha. We classified adverse events into two groups, viz, (a) adverse events not requiring
any modification in interferon therapy (Table 2), and (b) adverse
events requiring modification or termination of treatment (Table

Failure of normalisation of ALT at the end of treatment was seen
in 65.2% patients treated with interferon alpha versus 98.7% in
the no intervention control group (RR 0.69, 95% CI 0.59 to 0.80,
P < 0.00001) (Analysis 2.3).

Failure of histological response
Assessment of histological response was restricted on a number of
accounts. Different trials were unable to repeat biopsies on all the
participants; this was especially true of untreated control group
participants. An assumption of no improvement in histology was
thus presumed in those with missing biopsy. Additionally, reporting of histological findings and grading of severity were performed
on different scales among the trials. We decided to assess histological outcome as a dichotomous variable with improvement noticed
or no improvement noticed among participants of a trial. There
was no histological improvement in 72.8% patients treated with
interferon alpha compared with 84.4% in controls (RR 0.86, 95%
CI 0.74 to 1.00, P = 0.06) (Analysis 2.5). There was no heterogeneity among the trials (I2 0 %, P = 0.50).

Subgroup analysis
We searched the trials for data on patients with hepatitis C virus
and HIV co-infection, alcoholism, patients using immunosuppressive drugs, and liver transplanted patients in order to perform
subgroup analyses. However, none of the trials fulfilling the inclusion criteria of the review protocol provided specific details of
the individual patients in this regard, and these subgroup analyses
could not be performed. However, we performed the subgroup
analysis comparing high median dose of interferon alpha with low
dose. Data about improvement in the quality of life were also not
available.
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Interferon alpha high dose compared with interferon
alpha low dose
Two trials, comparing a higher cumulative dose regimen with a
lower dose regimen of interferon alpha, failed to achieve sustained
virologic response in 76.7% of the patients with higher dose compared to 90% with the lower dose (RR 0.85, 95% CI 0.68 to
1.07), but this difference was not statistically significant (P = 0.16)
(Analysis 3.1; Analysis 3.2) (Farci 1994; Madejon 1994). There
was also no significant difference in biochemical response between
high dose and low dose interferon groups (Analysis 3.3; Analysis
3.4).

DISCUSSION

Summary of main results
Chronic hepatitis D aggravates the natural course of hepatitis B
infection. It is difficult to treat hepatitis D. Interferon is the only
treatment for chronic hepatitis D. Randomised clinical trials based
on interferon therapy were conducted in late 1980s and early
1990s. These trials are few. The response evaluated was clearance
of HDV RNA (virological response), normalisation of ALT (biochemical response), and histological improvement based on liver
biopsy. We found absence of significant sustained virological response, improvement in ALT, and histological improvement in
our analysis. We observed, however, a potential effect of interferon
on end of treatment virological and biochemical responses. These
observations are hampered by the risk of significant errors (bias)
and the risk of random error (play of chance). We, therefore, tend
to agree with Hughes et al (Hughes 2011): interferon alpha, standard or pegylated, seems to be the only effective therapy available
so far for HDV, though it may not be an ideal treatment. This
therapy may not cure the infection in all patients, but it may potentially benefit in some patients. Such potential effects come at a
price: increased risk of adverse events and of costs.
Interesting, although sustained virological response is not achieved
in all patients, biochemical response appears to correlate with improvement in liver histology. The beneficial effect lasts even beyond the termination of therapy. A 2 to 14 year follow-up study
of patients from Farci 1994 showed that high doses of interferon
alpha-2a (9 million units thrice a week) significantly improved the
long-term clinical outcome and survival of patients with chronic
hepatitis D, even though the majority had active cirrhosis before
the onset of therapy (Farci 2004). These patients had a sustained
decrease in HDV replication, leading to clearance of HDV RNA
and, eventually, hepatitis B virus (HBV) in some patients, as well
as a dramatic improvement in liver histology with respect to activity grade and brosis stage. So, the clearance of serum HDV

RNA associated with loss of HBsAg may occur years after discontinuation of treatment (Lau 1999). In patients, who do not clear
HDV RNA but do show biochemical and histological response,
interferon probably induces less pathogenic mutants (Ottobrelli
1991).
With the development of pegylated interferon, uncontrolled studies on hepatitis D have appeared in literature. Castelnau et al
showed an end of treatment virological response of 57% (8/14)
with pegylated interferon alpha 2b 1.5 microgram per kg and sustained virological response of 43% (Castelnau 2006). However,
another study of 12 patients using the same dose showed a sustained virological response of only 17% (Erhardt 2006). Negative
polymerase chain reaction (PCR) or decrease of more than three
logs in HDV RNA level at six months of intervention is correlated
with sustained virological response. In an international trial done
by Wedemeyer and colleagues (HIDIT-1), pegylated interferon
alpha 2a had a significant antiviral efficacy against HDV, with 28%
achieving a sustained virological response (Wedemeyer 2011).
HBsAg is required for production of viral hepatitis D particles,
and active suppression of this antigen seems, therefore, a must.
Few trials have compared the effectiveness of combination of one
of the nucleoside analogues or ribavirin with standard or pegylated
interferon versus interferon alone. These combinations failed to
show advantage of using combination over interferon monotherapy (Niro 2006). Available therapies do not effectively suppress
the surface antigen but do have some effect in reducing its level. For
example, lamivudine and famciclovir individually are ineffective
against HDV (Yurdaydin 2002; Niro 2005a). Four randomised trials comparing interferon monotherapy with lamivudine, adefovir
dipivoxil, or ribavirin combination with interferon failed to show
improvement in the virological and biochemical responses over interferon monotherapy (Gunsar 2005; Canbakan 2006; Yurdaydin
2008; Wedemeyer 2011). Inclusion of these more recent trials in
the analysis is beyond the scope of what was defined in the objectives of the current review.
There is a need to develop new therapies effective directly against
HDV. There are few reports of clearance of HBsAg in up to 11%
of the patients of hepatitis B with one year of pegylated interferon therapy. Thus, monitoring of HBsAg levels along with HDV
RNA levels would be recommended in future trials to evaluate
response. Ideally treatment should be continued until the loss of
HBsAg. Monitoring HDV RNA levels could help in predicting
the response and adjusting the duration of therapy just as done for
hepatitis C (Lok 2007; EASL 2009; Ghany 2009) The HIDIT1 trial showed that combination of pegylated interferon with adefovir dipivoxil was superior to interferon monotherapy in reducing HBsAg levels (Wedemeyer 2011). There is a need for randomised trials comparing pegylated interferon monotherapy with
its combination with more powerful nucleos(t)ide analogues and
for longer duration. In the future, drugs directly acting on HDV
life cycle such as antisense oligonucleotides (Chen 1997), prenylation inhibitors (Bordier 2003), and HBV/HDV virus entry in-

Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

hibitors (Petersen 2008) would also have some role alone, or probably in combination with pegylated interferon.

Overall completeness and applicability of
evidence
From the available trials’ data we may conclude that interferon
alpha potentially seems effective in suppressing viral activity and
decreasing liver disease activity in some patients, but the inhibitory
effect is temporary, and improvement is not sustained in the majority of patients. From the limited data available, it is not possible
to find out any predictive factors or determinants of response. Due
to low sustained response, it seems difficult to accept this agent as
standard of care for hepatitis D. The possibility that pegylated interferon might be more effective needs further evaluation in clinical trials. The reason is that all included trials had high risk of bias
(systematic errors) and high risk of play of chance (random errors)
and we cannot exclude outcome measure reporting bias as well as
publication bias.

Agreements and disagreements with other
studies or reviews
Other reviews have also highlighted the limited efficacy of interferon alpha against hepatitis D (Malaguarnera 1996; Farci 2003;
Niro 2005; Farci 2007; Wedemeyer 2010). They have mentioned
the individual studies and have drawn conclusions without performing meta-analysis. There is one meta-analysis available which
has been done by Hadziyannis (Hadziyannis 1991). However, it is
based on biochemical response, and used reduction in ALT levels as
the primary outcome measure. While we did the systematic review
comparing the trials in clinically relevant outcome measures such
as mortality, virological, biochemical, and histological responses
at the end of treatment and the end of the follow-up period and
calculated the meta-analysis results. We also did subgroup analysis
comparing high dose with low dose of interferon.

AUTHORS’ CONCLUSIONS
Implications for practice

Quality of the evidence
Data from the available randomised trials were difficult to compare due to the small number of trials and differences in the dose,
duration, and agents used in combination. In addition to methodological heterogeneity, only one subgroup analysis could be conducted. All trials were unblinded, and several of them also showed
other bias risks. Allocation concealment was not observed or was
not clear. However, these trials were considered free from selective
reporting and incomplete outcome data were adequately addressed
by most of the trials. Assessment was based on an intention-totreat principle. Possibility of publication bias cannot be excluded,
and the risk of bias in the included trials was high.

Potential biases in the review process
We did not limit our search to English language publications only.
However, the databases we searched contain less number of journals indexed from the developing world. We tried to retrieve the
unpublished data by going through the abstracts from liver meetings. Data of an unpublished trial were generously provided by
their authors. However, during the process of writing the review,
the study got published (Wedemeyer 2011). This meta-analysis
is based on a small number of trials, with each trial comprising
a small sample size compounded by the differing dosage and duration of interferon administration. These limitations carry over
into our analysis, and in our opinion, restricts definitive conclusion regarding this treatment.

Administration of interferon to patients with chronic hepatitis D
can neither be supported nor refuted. Interferon may benefit some
patients through long-term remission. The patients run the risk
of adverse events and serious adverse events. Newer therapies are
needed.

Implications for research
Randomised clinical trials are needed to compare interferon alpha
versus placebo (or no placebo), pegylated interferon with standard
interferon, to determine duration of therapy, ie, 12 months versus
18 or 24 months, to document any improvement in response with
combination of newer, more powerful nucleoside or nucleotide
analogues, and to evaluate combination of pegylated interferon
with prenylation inhibitors or HBV/HDV virus entry inhibitors.
Other possible interventions ought to be assessed in chronic hepatitis D. A possible candidate could be a HBV/HDV virus entry
inhibitor. In the future, trials ought to be reported according to
the recommendations of CONSORT (http://www.consort-statement.org/).
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [author-defined order]
Porres 1989
Methods

Randomised clinical trial.
Sample size: no justification.
Intention-to-treat: yes.
Interim analyses: no.

Participants

Patients with chronic hepatitis D from Spain (n = 20).
Inclusion criteria: positive HDV-IgM antibody, biopsy proven chronic hepatitis with
intrahepatic delta antigen
Exclusion criteria: previous antiviral or steroid therapy, signs of active HBV infection,
ie, HBeAg or HBV DNA
Treatment and comparison groups similar at the start of study

Interventions

Control: no treatment (n =10).
Experimental 1: interferon alfa-2c 10 million units/square meter twice a week (n =10).
Duration: six months.
Follow-up: 9 months post treatment.

Outcomes

Loss of anti-HDV IgM.
Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.

Notes

Three patients with positive anti-HIV (two in control and one in treatment group.
Subgroup analyses were not performed in the trial

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

Quote “The patients were randomly allocated into two groups.” Method not mentioned

Allocation concealment (selection bias)

Not mentioned.

Unclear risk

Blinding (performance bias and detection High risk
bias)
All outcomes

Unblinded trial design.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

“ All the patients remained on the treatment until the end of the treatment period”

Selective reporting (reporting bias)

Low risk

Outcome measures adequately reported.
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Rosina 1989
Methods

Randomised clinical trial.
Sample size: no justification.
Intention-to-treat: yes.

Participants

Patients with chronic hepatitis D (n =24) from Italy.
Inclusion criteria: positive HDV antibody, elevated ALT for one year, histological evidence of chronic hepatitis and positive HDV antigen in liver Bx done within two months
Exclusion criteria: Not mentioned.

Interventions

Control: no treatment (n =12).
Experimental 1: interferon alfa-2b 5 million units (MU) t.i.w. (n =12).
Duration: 3 months.
Follow-up: 9 months post treatment.
Liver biopsy at enrolment and end of post treatment follow-up

Outcomes

Normalisation of ALT.
Improvement in liver histology.
Decrease in HDV RNA level.
Loss of HDV RNA.
Loss of HDV antigen in serum.

Notes

Second liver biopsy was done in only 4/12 controls.
Two patients in the control group were negative for HDV RNA at the time of enrolment,
end of treatment, and end of follow-up and do not fulfil the criteria for response

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection High risk
bias)

Quote“ the patients were matched for age
and sex, randomly assigned to a treated or
control group”. It is mentioned in the abstract but not described in the “Materials and Methods” section. In the comparison table, standard deviations for the age at
baseline were not mentioned, and baseline
ALT levels were not given

Allocation concealment (selection bias)

No.

High risk

Blinding (performance bias and detection High risk
bias)
All outcomes

Unblinded trial design.

Incomplete outcome data (attrition bias)
All outcomes

High risk

Second liver biopsy was done in only 4/12
controls.

Selective reporting (reporting bias)

Low risk

Outcome measures adequately reported.
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Rosina 1991
Methods

Sample size: not calculated.
Intention-to-treat: yes.

Participants

Patients with chronic hepatitis D (n =61) from Italy.
Inclusion criteria: positive HDV antibody, elevated ALT for one year, histological evidence of chronic hepatitis or cirrhosis, and positive staining for HDAg on liver Bx done
within six months
Exclusion criteria were: previous interferon therapy, decompensated cirrhosis, concomitant severe illness, proven drug abuse, prothrombin time greater than 4 s prolonged,
platelets < 100,000/cmm, WBC < 3000/cmm, granulocytes < 1500/cmm, creatinine >
1.7 mg/dl, anti-HIV antibodies

Interventions

Control: no treatment (n = 30).
Experimental 1: interferon alfa-2b 5 million units (MU) t.i.w. for 4 months, 3 MU thrice
a week for 8 months.Duration: 1 year (n = 31).
Follow-up: 1 year post treatment.
Liver biopsy at enrolment and second month of post treatment follow-up

Outcomes

Normalisation of ALT.
Improvement in liver histology.
Decrease in HDAg in liver biopsy.
Loss of HDV RNA.

Notes

Drop outs/withdrawals = 13; 5 from the treatment group and 8 from no treatment. Reasons were ulcer at the injection site in1, acute icteric hepatitis in 1, and non-compliance
3 in the treatment group and 8 in the control group. Intention-to-treat analysis done.
However, authors preferred per protocol analysis for the histological improvement

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote “Study patients were randomly assigned to the treatment or control group
(no placebo) using a computer-generated
randomisation code.”

Allocation concealment (selection bias)

Not mentioned.

Unclear risk

Blinding (performance bias and detection High risk
bias)
All outcomes

Unblinded trial design.

Incomplete outcome data (attrition bias)
All outcomes

High risk

There were thirteen (out of 61 patients)
dropouts during study period. Quote “Of
these 61 patients, 48 (79%) have completed 24 months of the study”

Selective reporting (reporting bias)

Low risk

Outcome measures adequately reported.
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Farci 1994
Methods

Sample size: no justification.
Generation of allocation schedule: by computer.
Allocation concealment: yes.
Intention-to-treat: yes.
Interim analyses: no.

Participants

Patients with chronic hepatitis D (n = 42) from Italy.
Inclusion criteria: age 18 to 60, positive HDV antibody, serum HDV RNA documented
on three occasions in the last six months, elevated ALT for six months, histological
evidence of chronic hepatitis, positive test for intrahepatic delta antigen, no signs of
active HBV infection
Exclusion criteria were: antiviral therapy within six months, pregnancy, lactation, decompensated cirrhosis, clotting abnormalities precluding liver biopsy, hepatocellular carcinoma, WBC < 3000/cmm, platelets < 100,000/cmm

Interventions

Control: no treatment (n =14).
Experimental 1: interferon alfa-2a 9 million units thrice a week (n =14)
Experimental 2:interferon alfa-2a 3 million units thrice a week (n =14).
Duration : 48 weeks.
Follow-up: 6 months post treatment.
Long term follow-up: mean 32 months (24 to 48).

Outcomes

Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.

Notes

One patient lost to follow-up in the control group. Intention to treat analysis was done
throughout. Experimental 1 and 2 groups were taken together and compared with the
control group. Control group did not get end of treatment biopsy. However, all groups
offered six months post treatment biopsy, and these data were used for analysis of histological improvement

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Computer-generated.

Allocation concealment (selection bias)

“Using computer-generated sealed envelopes, we randomly assigned patients...”
It does not mention whether the envelops
were opaque or not

Unclear risk

Blinding (performance bias and detection High risk
bias)
All outcomes
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Farci 1994

(Continued)

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Quote “All patients with the exception of
one in the control group were evaluated at
the end of six months of follow-up.”

Selective reporting (reporting bias)

Low risk

Outcome measures adequately reported.

Madejon 1994
Methods

Sample size: calculated.
Generation of allocation schedule: by computer.
Allocation concealment: not used.
Intention-to-treat analysis: yes.
Interim analyses: no.

Participants

Patients with chronic hepatitis D (n =32) from Spain. Inclusion criteria: positive HDV
antibody, presence of serum HDV RNA documented in the last six months, elevated
ALT for six months, histological evidence of chronic hepatitis or cirrhosis. Six patients
(18%) had anti-HCV and 2 (6%) anti-HIV antibodies. Exclusion criteria were: antiviral
or immunosuppressive therapy within one year, decompensated cirrhosis (Child B or C)
, concomitant severe illness, proven active drug abuse, prothrombin time less than 50%
of normal valve, platelets < 75,000/cmm

Interventions

Experimental 1: interferon alfa-2a 18 million units (MU) thrice a week for 6 months,
9 MU thrice a week for 1 month, 6 MU t.i.w. for 1 month, 3 MU thrice a week for 4
months (n =16) .
Experimental 2: interferon alfa-2a 3 million units daily for 3 months then 1.5 MU daily
for 9 months (n =16).
Duration : 1 year.
Follow-up: 18 months post treatment.
Liver biopsy at enrolment and second month of post-treatment follow-up

Outcomes

Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.

Notes

Drop outs/withdrawals = 7; 3 from low dose and 4 from high dose. Reasons were: return
to active drug abuse (n =2), neuropsychiatric disorder (n =2), thrombocytopoenia (n =
2), and voluntary withdrawal (n =1). Intention to treat analysis was done throughout.
Histological improvement was less than 2 points
No end of treatment biopsy available. Liver biopsy was done after 18 months posttreatment follow-up period

Risk of bias
Bias

Authors’ judgement
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Madejon 1994

(Continued)

Random sequence generation (selection Low risk
bias)

Quote “ The patients were randomly allocated into two groups by means of a computer random-sample generation.”

Allocation concealment (selection bias)

Not mentioned.

Unclear risk

Blinding (performance bias and detection High risk
bias)
All outcomes

Unblinded trial design.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Quote “All but seven (three from group
I and four from group II) finished the
treatment period... All dropout patients
had persistently increased ALT values and
HDV RNA positivity when they left the
study.” Missing outcomes data balanced
across groups

Selective reporting (reporting bias)

Low risk

Outcome measures adequately reported.

Gaudin 1995
Methods

Sample size: not calculated.
Randomisation: performed effectively.
Generation of allocation schedule: by computer-generated randomisation code.
Allocation concealment: not used.
Intention-to-treat: yes.
Interim analyses: no.

Participants

Patients with chronic hepatitis D (n =22) from France.
Inclusion criteria: age 18 to 65, positive HDV antibody, serum HDV RNA documented
in the last six months, elevated ALT (> 1.5 times normal) on three occasions for six
months, histological evidence of chronic hepatitis, positive test for intrahepatic delta
antigen, no signs of active HBV infection
Exclusion criteria were: antiviral therapy within 24 months, pregnancy, lactation, decompensated cirrhosis, clotting abnormalities precluding liver biopsy, hepatocellular carcinoma, WBC < 3000/cmm, platelets < 100,000/cmm, alcoholism or other drug addiction, or HIV positivity

Interventions

Control: no treatment (n =11).
Experimental 1: interferon alfa-2a 5 million units/m2 body surface area thrice a week
for 4 months, then 3MU/m2 for 8 months (n =11).
Duration : 52 weeks.
Follow-up: 18 months post treatment.

Outcomes

Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.
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Gaudin 1995

(Continued)

Notes

Therapy was discontinued in two patients, one at 4 mo because of induction of hyperthyroidsm and other at 11 months because of death by suicide. Intention to treat analysis
was done throughout. Histological improvement was less than 2 points

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote, ” ... were randomly allocated to receive either no treatment or IFN-a using a
computer generated randomisation code

Allocation concealment (selection bias)

Not mentioned.

Unclear risk

Blinding (performance bias and detection High risk
bias)
All outcomes

Not possible with the trial design

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Therapy was discontinued in two patients,
one at 4 months because of induction of
hyperthyroidsm and other at 11 months
because of death by suicide. Intention to
treat analysis was done throughout

Selective reporting (reporting bias)

Low risk

Outcome measures adequately reported.

t.i.w. = three times a week.
HDV = hepatitis D virus.
anti-HDV IgM = anti-hepatitis D virus antibody IgM.
HDAg = hepatitis D antigen.
ALT = alanine aminotransferase.

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Battegay 1994

Not a randomised clinical trial.

Berk 1991

Not a randomised clinical trial.

Borghesio 1995

Lymphoblastoid IFN 10 MU t.i.w (n = 8) compared with 5 MU daily (n = 6). Both groups treated up to
ALT normalization plus 12 months. Basically same dose with two different regimens. No control group. Interm
results
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(Continued)

Buti 1989

Not a randomised clinical trial.

Canbakan 2006

Interferon monotherapy compared with interferon plus lamivudine. Though a randomised trial, the trial does
not fit within the prespecified comparisons of the review

Castelnau 2006

Not a randomised clinical trial.

Craxi 1990

Not a randomised clinical trial.

Deny 1994

Not a randomised clinical trial.

Di Bisceglie 1990

Not a randomised clinical trial.

Di Marco 1996

Not a randomised clinical trial. One year treatment compared with two year treatment. Two groups enrolled
sequentially; first one year treatment group and then two year treatment group. No control group. Low dose
interferon given to both groups

Erhardt 2006

Not a randomised clinical trial.

Farci 1989

Not a randomised clinical trial.

Gunsar 2005

Interferon monotherapy compared with interferon plus ribavirin. Though a randomised trial, the trial does not
fit within the prespecified comparisons of the review

Kaymakoglu 2005

Not a randomised clinical trial.

Lau 1993

Not a randomised clinical trial. Eleven patients, out of which five treated after one year of observation. Data
analysed together. HDV RNA not available. SVR not clear

Lau 1999

Not a randomised clinical trial. Follow-up of a single patient

Manesis 2007

Not a randomised clinical trial.

Marinucci 1991

Not a randomised clinical trial.

Marzano 1992

Not a randomised clinical trial.

Puoti 1998

Not a randomised clinical trial.

Rizzetto 1986

Not a randomised clinical trial.

Rumi 1995 A

Not a randomised clinical trial.

Rumi 1995 B

Not a randomised clinical trial.

Schneieder 1998

Not a randomised clinical trial.

Taillan 1988

Not a randomised clinical trial.
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(Continued)

Wedemeyer 2011

Pegylated interferon monotherapy compared with pegylated interferon plus adefovir and adefovir monotherapy.
Though a randomised trial, the trial does not fit within the prespecified comparisons of the review

Wolters 2000

Not a randomised clinical trial.

Yurdaydin 2007

Not a randomised clinical trial.

Yurdaydin 2008

Interferon monotherapy compared with interferon plus lamivudine and adefovir monotherapy. Though a randomised trial, the trial does not fit within the prespecified comparisons of the review

t.i.w. = three times a week.
SVR = sustained virological response.
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DATA AND ANALYSES

Comparison 1. Mortality

Outcome or subgroup title
1 Interferon alpha versus no
intervention

No. of
studies

No. of
participants

5

169

Statistical method
Risk Ratio (M-H, Random, 95% CI)

Effect size
3.00 [0.14, 66.53]

Comparison 2. Interfeon alpha 2a versus no treatment for hepatitis D

Outcome or subgroup title
1 Failure of virological response:
end of treatment
2 Failure of virological response:
six months after completion of
treatment
3 Failure of biochemical response:
end of treatment
4 Failure of biochemical response:
six months after completion of
treatment
5 Failure of histological response

No. of
studies

No. of
participants

5

169

Risk Ratio (M-H, Fixed, 95% CI)

0.76 [0.66, 0.87]

5

169

Risk Ratio (M-H, Fixed, 95% CI)

0.89 [0.80, 0.98]

5

169

Risk Ratio (M-H, Fixed, 95% CI)

0.69 [0.59, 0.80]

5

169

Risk Ratio (M-H, Fixed, 95% CI)

0.92 [0.84, 0.99]

5

169

Risk Ratio (M-H, Fixed, 95% CI)

0.86 [0.74, 1.00]

Statistical method

Effect size

Comparison 3. Higher dose of standard interferon versus lower dose

Outcome or subgroup title
1 Failure of virological response:
end of treatment
2 Failure of virological response:
six months after completion of
treatment
3 Failure of biochemical response:
end of treatment
4 Failure of biochemical response:
Six months after completion of
treatment

No. of
studies

No. of
participants

2

60

Risk Ratio (M-H, Fixed, 95% CI)

0.79 [0.59, 1.05]

2

60

Risk Ratio (M-H, Fixed, 95% CI)

0.85 [0.68, 1.07]

2

60

Risk Ratio (M-H, Fixed, 95% CI)

1.0 [0.75, 1.33]

2

60

Risk Ratio (M-H, Fixed, 95% CI)

1.10 [0.84, 1.43]

Statistical method
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Analysis 1.1. Comparison 1 Mortality, Outcome 1 Interferon alpha versus no intervention.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 1 Mortality
Outcome: 1 Interferon alpha versus no intervention

Study or subgroup

Interferon alpha

No
intervention
control

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Farci 1994

0/28

0/14

Gaudin 1995

1/11

0/11

Porres 1989

0/10

0/10

Not estimable

Rosina 1989

0/12

0/12

Not estimable

Rosina 1991

0/31

0/30

Not estimable

92

77

Total (95% CI)

Not estimable
100.0 %

100.0 %

3.00 [ 0.14, 66.53 ]

3.00 [ 0.14, 66.53 ]

Total events: 1 (Interferon alpha), 0 (No intervention control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable

0.01

0.1

Favours interferon alpha

1

10

100

Favours no intervention
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Analysis 2.1. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 1 Failure of
virological response: end of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 1 Failure of virological response: end of treatment

Interferon alpha

No
treatment
(control)

n/N

n/N

13/28

14/14

24.6 %

0.48 [ 0.32, 0.72 ]

Gaudin 1995

4/11

7/11

9.0 %

0.57 [ 0.23, 1.41 ]

Porres 1989

7/10

8/10

10.3 %

0.88 [ 0.53, 1.46 ]

Rosina 1989

8/12

12/12

16.1 %

0.68 [ 0.45, 1.02 ]

Rosina 1991

30/31

30/30

39.9 %

0.97 [ 0.89, 1.06 ]

92

77

100.0 %

0.76 [ 0.66, 0.87 ]

Study or subgroup

Farci 1994

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 62 (Interferon alpha), 71 (No treatment (control))
Heterogeneity: Chi2 = 35.36, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 2 Failure of
virological response: six months after completion of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 2 Failure of virological response: six months after completion of treatment

Interferon

No
treatment
(control)

n/N

n/N

Rosina 1989

11/12

12/12

15.9 %

0.92 [ 0.74, 1.15 ]

Porres 1989

5/10

8/10

10.2 %

0.63 [ 0.31, 1.25 ]

Rosina 1991

30/31

30/30

39.3 %

0.97 [ 0.89, 1.06 ]

Farci 1994

20/28

13/14

22.0 %

0.77 [ 0.58, 1.01 ]

Gaudin 1995

10/11

10/11

12.7 %

1.00 [ 0.77, 1.30 ]

92

77

100.0 %

0.89 [ 0.80, 0.98 ]

Study or subgroup

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 76 (Interferon), 73 (No treatment (control))
Heterogeneity: Chi2 = 6.74, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 3 Failure of
biochemical response: end of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 3 Failure of biochemical response: end of treatment

Interfeon

No
treatment
(control)

n/N

n/N

Rosina 1989

8/12

12/12

15.1 %

0.68 [ 0.45, 1.02 ]

Porres 1989

8/10

10/10

12.7 %

0.81 [ 0.57, 1.14 ]

Rosina 1991

23/31

30/30

37.4 %

0.75 [ 0.60, 0.92 ]

Farci 1994

14/28

13/14

20.9 %

0.54 [ 0.36, 0.80 ]

Gaudin 1995

7/11

11/11

13.9 %

0.65 [ 0.41, 1.03 ]

Total (95% CI)

92

77

100.0 %

0.69 [ 0.59, 0.80 ]

Study or subgroup

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 60 (Interfeon), 76 (No treatment (control))
Heterogeneity: Chi2 = 2.93, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 4.93 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 4 Failure of
biochemical response: six months after completion of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 4 Failure of biochemical response: six months after completion of treatment

Interferon

No
treatment
(control)

n/N

n/N

Porres 1989

10/10

10/10

12.7 %

1.00 [ 0.83, 1.20 ]

Rosina 1989

11/12

12/12

15.1 %

0.92 [ 0.74, 1.15 ]

Rosina 1991

30/31

30/30

37.4 %

0.97 [ 0.89, 1.06 ]

Farci 1994

20/28

13/14

20.9 %

0.77 [ 0.58, 1.01 ]

Gaudin 1995

10/11

11/11

13.9 %

0.91 [ 0.72, 1.17 ]

92

77

100.0 %

0.92 [ 0.84, 0.99 ]

Study or subgroup

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 81 (Interferon), 76 (No treatment (control))
Heterogeneity: Chi2 = 3.96, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 5 Failure of
histological response.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 5 Failure of histological response

Interferon

No
treatment
(control)

n/N

n/N

Porres 1989

10/10

10/10

14.9 %

1.00 [ 0.83, 1.20 ]

Rosina 1989

11/12

12/12

17.8 %

0.92 [ 0.74, 1.15 ]

Rosina 1991

20/31

25/30

36.1 %

0.77 [ 0.57, 1.05 ]

Farci 1994

21/28

12/14

22.7 %

0.88 [ 0.65, 1.18 ]

Gaudin 1995

5/11

6/11

8.5 %

0.83 [ 0.36, 1.94 ]

Total (95% CI)

92

77

100.0 %

0.86 [ 0.74, 1.00 ]

Study or subgroup

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 67 (Interferon), 65 (No treatment (control))
Heterogeneity: Chi2 = 3.37, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 1 Failure of
virological response: end of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 1 Failure of virological response: end of treatment

Study or subgroup

Farci 1994
Madejon 1994

Total (95% CI)

High dose

Low dose

n/N

n/N

Risk Ratio

Weight

4/14

9/14

37.5 %

0.44 [ 0.18, 1.11 ]

15/16

15/16

62.5 %

1.00 [ 0.84, 1.20 ]

30

30

100.0 %

0.79 [ 0.59, 1.05 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 19 (High dose), 24 (Low dose)
Heterogeneity: Chi2 = 8.08, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 2 Failure of
virological response: six months after completion of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 2 Failure of virological response: six months after completion of treatment

Study or subgroup

Farci 1994
Madejon 1994

Total (95% CI)

High dose

Low dose

n/N

n/N

Risk Ratio

Weight

8/14

12/14

44.4 %

0.67 [ 0.40, 1.10 ]

15/16

15/16

55.6 %

1.00 [ 0.84, 1.20 ]

30

30

100.0 %

0.85 [ 0.68, 1.07 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 23 (High dose), 27 (Low dose)
Heterogeneity: Chi2 = 4.00, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 3 Failure of
biochemical response: end of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 3 Failure of biochemical response: end of treatment

Study or subgroup

High dose

Low dose

n/N

n/N

Farci 1994

12/14

9/14

39.1 %

1.33 [ 0.85, 2.08 ]

Madejon 1994

11/16

14/16

60.9 %

0.79 [ 0.54, 1.15 ]

30

30

100.0 %

1.00 [ 0.75, 1.33 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 23 (High dose), 23 (Low dose)
Heterogeneity: Chi2 = 3.16, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 4 Failure of
biochemical response: Six months after completion of treatment.
Review:

Interferon alpha for chronic hepatitis D

Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 4 Failure of biochemical response: Six months after completion of treatment

Study or subgroup

High dose

Low dose

n/N

n/N

8/14

6/14

28.6 %

1.33 [ 0.63, 2.84 ]

15/16

15/16

71.4 %

1.00 [ 0.84, 1.20 ]

30

30

100.0 %

1.10 [ 0.84, 1.43 ]

Farci 1994
Madejon 1994

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 23 (High dose), 21 (Low dose)
Heterogeneity: Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable

0.2

0.5

Favours high dose

1

2

5

Favours low dose

ADDITIONAL TABLES
Table 1. Male:female ratio
Study ID

Male

Female

Porres 1989

15

5

Rosina 1989

22

2

Rosina 1991

54

7

Farci 1994

35

7

Madejon 1994

26

6

Gaudin 1995

22

0

Total

174

27
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Table 2. Adverse events related to interferon therapy

Study ID

Adverse events listed

Percentage of patients

Porres 1989

Flu-like symptoms
Weight loss
Leukopoenia
Thrombocytopoenia

100
40
30
40

Rosina 1989

Flu-like symptoms
Transient hair loss
Herpes labialis
Granuloopoenia

100
33
25
67

Rosina 1991

Flu-like symptoms
Fatigue
Weight loss
Alopaecia
Nausea/Anorexia
Vomiting
Impaired consciousness
Rhinorrhea

100
100
100
17
35
6
3
3

Farci 1994

Flu-like symptoms
Asthenia
Alopaecia
Anemia

100
50
43
4

Madejon 1994

Asthenia
Anorexia
Fever
Weight loss
Arthralgias
Hair loss
Headache
Itching

56
50
47
47
41
38
38
12

Gaudin 1995

Flu-like symptoms
Leukopoenia
Thrombocytopoenia
Hyperthyroidism
Death (by suicide)

100
100
100
10
10
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Table 3. 2 Adverse events requiring dose modification or termination of interferon therapy

Study ID

Events*

Total number of participants

%

Porres 1989

0

10

0

Rosina 1989

0

12

0

Rosina 1991

16

31

51.6

Farci 1994

2

28

7.1

Gaudin 1995

4

11

36.4

Madejon 1994

7

32

21.9

Total

29

124

23.4

Total number of participants are the patients who received interferon. Events represent number of participants experiencing adverse
events requiring dose modification or termination of therapy

APPENDICES
Appendix 1. Search strategies

Database

Time Span

Search strategy

The Cochrane Hepato-Biliary Group Con- May 2011
trolled Trials Register

(*interferon* OR peg-ifn OR pegasus OR pegasys OR pegintron
OR ’viraferon peg’) AND ’hepatitis D’

Cochrane Central Register of Controlled Issue 2, 2011
Trials (CENTRAL) in The Cochrane Library

#1 MeSH descriptor Interferon-alphaexplode all trees in MeSH
products
#2 interferon* or pegylated interferon or peginterferon or peg-ifn
or pegas*s or pegintron or viraferon peg in All Fieldsin all products
#3 (#1 OR #2)
#4 MeSH descriptor Hepatitis Dexplode all trees in MeSH products
#5 hepatitis NEXT d in All Fieldsin all products
#6 (#4 OR #5)
#7 (#3 AND #6)
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(Continued)

MEDLINE (Ovid SP)

1950 to May 2011

1. exp Interferon-alpha/
2. (interferon* or pegylated interferon or peginterferon or peg-ifn
or pegas*s or pegintron or viraferon peg).mp. [mp=title, original
title, abstract, name of substance word, subject heading word]
3. 1 or 2
4. exp Hepatitis D/
5. hepatitis d.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
6. 4 or 5
7. 6 and 3
8. (random* or blind* or placebo* or meta-analysis).mp. [mp=title,
original title, abstract, name of substance word, subject heading
word]
9. 8 and 7

EMBASE (Ovid SP)

1980 to May 2011

1. exp Alpha Interferon/
2. (interferon* or pegylated interferon or peginterferon or peg-ifn
or pegas*s or pegintron or viraferon peg).mp. [mp=title, abstract,
subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]
3. 1 or 2
4. exp Delta Agent Hepatitis/
5. hepatitis d.mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device manufacturer, drug
manufacturer name]
6. 4 or 5
7. 6 and 3
8. (random* or placebo* or blind* or meta-analysis).mp. [mp=
title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name]
9. 8 and 7

Science Citation Index Expanded (http:// 1900 to May 2011
apps.isiknowledge.com)

#5 #4 AND #3
#4 TS=(random* or blind* or placebo* or meta-analysis)
#3 #2 AND #1
#2 TS=(hepatitis D)
#1 TS=(interferon* or pegylated interferon or peginterferon or
peg-ifn or pegas*s or pegintron or viraferon peg)
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